Ropes & Gray advised ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a research collaboration with Biosion USA, a global research & development biotechnology company, to create novel antibody-drug conjugates. The collaboration was announced on December 13. Financial terms were not disclosed.
In the joint research effort, Biosion will leverage its high-throughput endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their linker-payload technology to create novel ADCs.
The Ropes & Gray team was led by life sciences licensing partner Amanda Austin and IP transactions associate Sarah Smith.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.